分子量:25.5 kDa

纯度:>92% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Biotinylated Human FCGR3A / CD16a (F158) by the LAL method.

Buffer:PBS, pH7.4

生物活性:The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay.
Immobilized Biotinylated Human FCGR3A / CD16a (F158) Protein (Cat# CDA-H82E8) can bind Ipilimumab with affinity constant of around 784 nM.


产品特性:This protein carries a 15 AA fragment at the C-terminus, followed by a polyhistidine tag. There is one single lysine residue within the 15 AA fragment that is enzymatically labeled with biotin in vivo. The protein has a calculated MW of 25.5 kDa. The predicted N-terminus is Gly 17. The reducing (R) protein migrates as 40-55 kDa in SDS-PAGE due to glycosylation.

产品背景:CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed  natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.